People: Pain Therapeutics Inc (PTIE.O)

Summary

Name	Age	Since	Current Position
Remi Barbier	52	1998	Chairman of the Board, President, Chief Executive Officer
Nadav Friedmann	69	2004	Chief Medical and Operating Officer, Director
Peter Roddy	53	2004	Chief Financial Officer, Vice President
Grant Schoenhard	67	2001	Chief Scientific Officer
Michael O' Donnell	53		Secretary, Independent Director
Robert Gussin	74	2003	Independent Director
Saira Ramasastry		2013	Independent Director
Sanford Robertson	81	1998	Independent Director
Patrick Scannon	65	2007	Independent Director

» Insider Trading

Biographies

Name	Description
Remi Barbier	Mr. Remi Barbier is Chairman of the Board, President and Chief Executive Officer of Pain Therapeutics, Inc., since May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company, ArQule, Inc., a chemistry company, and EnzyMed, Inc. (now owned by Albany Molecular Research, Inc.), a chemistry company. Mr. Barbier served as Chief Operating Officer of Exelixis, Inc. from January 1996 to May 1998. Mr. Barbier was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company, from October 1993 to December 1995. Mr. Barbier is a trustee of the Carnegie Institute of Washington and is on the Advisory Board of the California Institute for Quantitative Biosciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
Nadav Friedmann	Dr. Nadav Friedmann, Ph.D., M.D., is Chief Medical and Operating Officer and Director of Pain Therapeutics, Inc. He has served as a director since 1998. Dr. Friedmann has served as Chief Operating Officer since October 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann is the owner and President of EMET Research Inc., a consulting firm in the pharmaceutical industry. Dr. Friedmann was President and Chief Executive Officer of Daiichi Pharmaceutical Corporation, a pharmaceutical company, from 1997 to April 2000, and was a consultant to the Board of Directors of Daiichi Pharmaceutical Co., Ltd. in Tokyo from 1995 to 1997. From 1992 to 1995, Dr. Friedmann served as Vice President, Clinical Research at Xoma Ltd. (formerly Xoma Corporation). From 1980 to 1991, Dr. Friedmann held various leadership positions with Johnson & Johnson (“J&J”), including the position of Vice President and Head of Research of the J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
Peter Roddy	Mr. Peter S. Roddy is Chief Financial Officer and Vice President of Pain Therapeutics, Inc. He has served as Chief Financial Officer since 2002 and as Vice President and Chief Financial Officer since 2004. From 1990 to 2002, Mr. Roddy held a variety of senior management positions at COR Therapeutics, Inc., a biopharmaceutical company, including Senior Vice President, Finance and Chief Financial Officer between 2000 and 2002. Prior to 1990, Mr. Roddy held a variety of positions at Price Waterhouse & Company, Hewlett Packard Company and MCM Laboratories, Inc. Mr. Roddy is a director of Vermillion, Inc., a publicly-held medical diagnostics company. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.
Grant Schoenhard	Dr. Grant L. Schoenhard, Ph.D., is Chief Scientific Officer of Pain Therapeutics Inc., since 2001. From 2000 to 2001, Dr. Schoenhard was the Vice President of Preclinical Development. During 2000, Dr. Schoenhard was a consultant and provided pharmacodynamic research and development services to various organizations. From 1998 to 2000, Dr. Schoenhard was Senior Director of Pharmacokinetics, Drug Metabolism and Pharmacology at Genentech, Inc., a biotechnology company. From 1974 to 1998, Dr. Schoenhard held various management positions, including Executive Director of Pharmacokinetics, Drug Metabolism and Radiochemistry at Searle, a pharmaceutical company owned by Monsanto Corporation. Dr. Schoenhard was also Adjunct Professor of Pharmacology, School of Medicine, University of Pennsylvania for a number of years. Dr. Schoenhard received his B.S. from Michigan State University and his M.S. and Ph.D. from Oregon State University.
Michael O' Donnell	Mr. Michael J. O' Donnell, Esq., is Secretary and Independent Director of Pain Therapeutics Inc. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011, Mr. O’Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation, or WSGR. Morrison & Foerster, LLP is the Company’s corporate counsel in 2011 and continues to provide legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.
Robert Gussin	Dr. Robert Z. Gussin, Ph.D., is Independent Director of Pain Therapeutics Inc., since March 2003. Dr. Gussin worked at J&J for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Prior to assuming this role, Dr. Gussin worked at J&J’s McNeil division for 12 years, most recently as Vice President, Research and Development and Vice President, Scientific Affairs. From 1967 to 1974, Dr. Gussin held various research positions with Lederle Laboratories, a pharmaceutical company. Dr. Gussin sits on the Board of Directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.
Saira Ramasastry	Ms. Saira Ramasastry has been appointed as Independent Director of Pain Therapeutics, Inc. She is the Founder and Managing Partner of Life Sciences Advisory, LLC, a firm that provides strategic business advice for the biopharmaceutical industry. Previously, Saira was an investment banker at Merrill Lynch & Co., where she was responsible for originating M&A, strategic and capital markets transactions in the biotechnology industry. Prior to Merrill Lynch, she worked in the M&A group at Wasserstein Perella & Co. She received a B.A. with Honors and Distinction and an M.S. from Stanford University, where she graduated Phi Beta Kappa, and a M. Phil. from the University of Cambridge. She serves on the Industry Advisory Board for the Michael J. Fox Foundation for Parkinson's Research, the Board of the American Liver Foundation, the Board of Sangamo Biosciences (Nasdaq:SGMO) and serves on the Cambridge Judge Business School Advisory Council.
Sanford Robertson	Mr. Sanford R. Robertson is Independent Director of Pain Therapeutics Inc., since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank formed in 1978 and sold to BankBoston in 1998. Since the sale, Mr. Robertson has been a technology investor and advisor to several technology companies. Mr. Robertson was also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities, another technology investment bank. Mr. Robertson is a director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications, Dolby Laboratories, Inc., a publicly-held entertainment technology company, and RPX, Inc., a publicly-held provider of patent risk solutions. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.
Patrick Scannon	Dr. Patrick J. Scannon, M.D., Ph.D., is Independent Director of Pain Therapeutics Inc., since 2007. Dr. Scannon is a director of and one of the founders of XOMA, Ltd. Dr. Scannon has been Executive Vice President, Chief Biotechnology Officer of XOMA Ltd. since 2006. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA, Ltd. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.

Basic Compensation

Name	Fiscal Year Total
Remi Barbier	3,147,950
Nadav Friedmann	1,438,760
Peter Roddy	1,001,340
Grant Schoenhard	904,742
Michael O' Donnell	--
Robert Gussin	--
Saira Ramasastry	--
Sanford Robertson	--
Patrick Scannon	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Remi Barbier	1,453,468	458,019
Nadav Friedmann	1,221,790	877,335
Peter Roddy	515,000	978,350
Grant Schoenhard	517,592	163,268
Michael O' Donnell	0	0
Robert Gussin	0	0
Saira Ramasastry	0	0
Sanford Robertson	0	0
Patrick Scannon	0	0

Insider Trading

Name	Shares Traded	Price
GUSSIN ROBERT Z	32,510	$5.41
GUSSIN ROBERT Z	25,738	$4.18
GUSSIN ROBERT Z	42,897	$4.49
GUSSIN ROBERT Z	19,887	$5.41
GUSSIN ROBERT Z	42,897	$4.10
GUSSIN ROBERT Z	35,603	$5.41
O DONNELL MICHAEL J	32,904	$5.36
O DONNELL MICHAEL J	42,897	$4.10
ROBERTSON SANFORD R	42,897	$4.10
BARBIER REMI	2,000,000	$0.00
BARBIER REMI	1,500	$0.00
BARBIER REMI	2,000,000	$0.00
BARBIER REMI	2,700	$0.00
BARBIER REMI	37,400	$0.00
BARBIER REMI	13,600	$0.00
BARBIER REMI	3,533	$2.29
RODDY PETER STUART	596	$2.51
FRIEDMANN NADAV	2,108	$2.51
RODDY PETER STUART	11,032	$0.00
SCHOENHARD GRANT L	11,032	$0.00
BARBIER REMI	36,775	$0.00
BARBIER REMI	110,325	$0.00
FRIEDMANN NADAV	55,162	$0.00
FRIEDMANN NADAV	3,622	$3.45
RODDY PETER STUART	4,346	$3.45

» Full list on Insider Trading

People: Pain Therapeutics Inc (PTIE.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: